Q3 EPS Estimates for AngioDynamics Cut by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Zacks Research lowered their Q3 2026 EPS estimates for shares of AngioDynamics in a research note issued on Tuesday, March 25th. Zacks Research analyst D. Dey now expects that the medical instruments supplier will earn ($0.05) per share for the quarter, down from their prior estimate of ($0.04). The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics' Q4 2026 earnings at $0.00 EPS, FY2026 earnings at ($0.28) EPS and FY2027 earnings at ($0.18) EPS.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business had revenue of $72.90 million during the quarter, compared to the consensus estimate of $70.93 million. During the same period last year, the company earned ($0.05) EPS. The company's revenue for the quarter was down .1% on a year-over-year basis.

Separately, HC Wainwright boosted their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, January 10th.

Remove Ads

AngioDynamics Price Performance

Shares of ANGO stock traded down $0.04 during trading on Friday, hitting $9.35. 172,196 shares of the stock traded hands, compared to its average volume of 569,631. The firm's fifty day moving average price is $10.35 and its 200-day moving average price is $8.82. The firm has a market capitalization of $378.36 million, a P/E ratio of -1.66 and a beta of 0.56. AngioDynamics has a 52-week low of $5.47 and a 52-week high of $13.50.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds have recently added to or reduced their stakes in ANGO. SBI Securities Co. Ltd. acquired a new stake in shares of AngioDynamics in the fourth quarter valued at $28,000. R Squared Ltd acquired a new stake in AngioDynamics in the 4th quarter valued at about $49,000. US Bancorp DE boosted its stake in shares of AngioDynamics by 1,938.0% in the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock valued at $61,000 after buying an additional 6,376 shares during the period. Quarry LP grew its position in shares of AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier's stock worth $66,000 after buying an additional 2,471 shares in the last quarter. Finally, Quinn Opportunity Partners LLC purchased a new stake in shares of AngioDynamics during the fourth quarter worth approximately $92,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares of the company's stock, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.